Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Cereb Blood Flow Metab ; 41(11): 3111-3126, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34176340

RESUMEN

Repetitive hypoxia (RH) exposure affects the initiation and progression of cognitive dysfunction, but little is known about the mechanisms of hypoxic brain damage. In this study, we show that sublethal RH increased anxiety, impaired learning and memory (L/M), and triggered downregulation of brain levels of glucose and several glucose metabolites in zebrafish, and that supplementation of glucose or glucosamine (GlcN) restored RH-induced L/M impairment. Fear conditioning (FC)-induced brain activation of and PKA/CREB signaling was abrogated by RH, and this effect was reversed by GlcN supplementation. RH was associated with decreased brain O-GlcNAcylation and an increased O-GlcNAcase (OGA) level. RH increased brain inflammation and p-Tau and amyloid ß accumulation, and these effects were suppressed by GlcN. Our observations collectively suggest that changes in O-GlcNAc flux during hypoxic exposure could be an important causal factor for neurodegeneration, and that supplementation of the HBP/O-GlcNAc flux may be a potential novel therapeutic or preventive target for addressing hypoxic brain damage.


Asunto(s)
Péptidos beta-Amiloides/metabolismo , Disfunción Cognitiva/metabolismo , Glucosamina/farmacología , Hipoxia/metabolismo , Pez Cebra/metabolismo , Proteínas tau/metabolismo , Animales , Ansiedad/metabolismo , Encéfalo/metabolismo , Estudios de Casos y Controles , Disfunción Cognitiva/etiología , Encefalitis/metabolismo , Femenino , Cromatografía de Gases y Espectrometría de Masas/métodos , Glucosamina/metabolismo , Glucosamina/uso terapéutico , Glucosa/metabolismo , Hipoxia/complicaciones , Hipoxia Encefálica/metabolismo , Hipoxia Encefálica/prevención & control , Discapacidades para el Aprendizaje/metabolismo , Masculino , Trastornos de la Memoria/metabolismo , N-Acetilglucosaminiltransferasas/metabolismo , Proteínas de Pez Cebra/metabolismo , beta-N-Acetilhexosaminidasas/metabolismo
2.
Methods Enzymol ; 602: 273-288, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29588034

RESUMEN

Xenon has features that make it an ideal general anesthetic agent; cost and scarcity mitigate xenon's widespread use in the operating room. Discovery of xenon's cytoprotective properties resulted in its application to thwart ongoing acute neurologic injury, an unmet clinical need. The discovery that xenon's neuroprotective effect interacts synergistically with targeted temperature management (TTM) led to its investigation in clinical settings, including in the management of the postcardiac arrest syndrome, in which TTM is indicated. Following successful demonstration of xenon's efficacy in combination with TTM in a preclinical model of porcine cardiac arrest, xenon plus TTM was shown to significantly decrease an imaging biomarker of brain injury for out of hospital cardiac arrest victims that had been successfully resuscitated. With the development of an efficient delivery system the stage is now set to investigate whether xenon improves survival, with good clinical outcome, for successfully resuscitated victims of a cardiac arrest.


Asunto(s)
Paro Cardíaco/complicaciones , Hipoxia Encefálica/prevención & control , Fármacos Neuroprotectores/farmacología , Xenón/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/patología , Ensayos Clínicos Fase III como Asunto , Terapia Combinada/métodos , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Paro Cardíaco/mortalidad , Paro Cardíaco/terapia , Humanos , Hipotermia Inducida/métodos , Hipoxia Encefálica/etiología , Hipoxia Encefálica/mortalidad , Fármacos Neuroprotectores/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptores de N-Metil-D-Aspartato/metabolismo , Resucitación/métodos , Porcinos , Resultado del Tratamiento , Xenón/uso terapéutico
3.
Amino Acids ; 48(8): 1955-67, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-26795537

RESUMEN

Creatine is of paramount importance for maintaining and managing cellular ATP stores in both physiological and pathological states. Besides these "ergogenic" actions, it has a number of additional "pleiotropic" effects, e.g., antioxidant activity, neurotransmitter-like behavior, prevention of opening of mitochondrial permeability pore and others. Creatine supplementation has been proposed for a number of conditions, including neurodegenerative diseases. However, it is likely that creatine's largest therapeutic potential is in those diseases caused by energy shortage or by increased energy demand; for example, ischemic stroke and other cerebrovascular diseases. Surprisingly, despite a large preclinical body of evidence, little or no clinical research has been carried out in these fields. However, recent work showed that high-dose creatine supplementation causes an 8-9 % increase in cerebral creatine content, and that this is capable of improving, in humans, neuropsychological performances that are hampered by hypoxia. In addition, animal work suggests that creatine supplementation may be protective in stroke by increasing not only the neuronal but also the endothelial creatine content. Creatine should be administered before brain ischemia occurs, and thus should be given for prevention purposes to patients at high risk of stroke. In myocardial ischemia, phosphocreatine has been used clinically with positive results, e.g., showing prevention of arrhythmia and improvement in cardiac parameters. Nevertheless, large clinical trials are needed to confirm these results in the context of modern reperfusion interventions. So far, the most compelling evidence for creatine and/or phosphocreatine use in cardiology is as an addition to cardioplegic solutions, where positive effects have been repeatedly reported.


Asunto(s)
Suplementos Dietéticos , Hipoxia Encefálica/prevención & control , Isquemia Miocárdica/prevención & control , Fosfocreatina/uso terapéutico , Accidente Cerebrovascular/prevención & control , Animales , Humanos , Hipoxia Encefálica/metabolismo , Isquemia Miocárdica/metabolismo , Fosfocreatina/farmacocinética , Accidente Cerebrovascular/metabolismo
4.
Artículo en Ruso | MEDLINE | ID: mdl-25536760

RESUMEN

This article presents the analysis of the current literature and the original data of the authors providing the rationale for the use of magnetic therapy for the treatment of the children presenting with cerebral ischemia taking into consideration pathogenesis of this disease. It is demonstrated that the application of the general magnetic field decreases the tone of the cerebral vessels and improves blood flow to the brain which increases resistance to cerebral hypoxia. The results of investigations into the microcirculatory changes and liquor dynamics in conjunction with the ventriculometric measurements give evidence of the effectiveness of the combined treatment of cerebral ischemia making use of general magnetic therapy.


Asunto(s)
Isquemia Encefálica/etiología , Isquemia Encefálica/rehabilitación , Magnetoterapia , Isquemia Encefálica/fisiopatología , Circulación Cerebrovascular/fisiología , Niño , Humanos , Hipoxia Encefálica/prevención & control , Microcirculación/fisiología
5.
Transfusion ; 54(8): 2045-54, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24673504

RESUMEN

BACKGROUND: Extracellular hemoglobin (Hb)-based oxygen carriers (HBOCs) are under extensive consideration as oxygen therapeutics. Their effects on cellular mechanisms related to apoptosis are of particular interest, because the onset of proapoptotic pathways may give rise to tissue damage. STUDY DESIGN AND METHODS: The objective was to assess whether the properties of the Hb that replaces blood during an isovolemic hemodilution would modulate apoptotic-response mechanisms in rat brain and whether such signaling favors cytoprotection or damage. We exposed rats to exchange transfusion (ET; 50% blood volume and isovolemic replacement with Hextend [negative colloid control], MP4OX [PEGylated HBOC with high oxygen affinity], and ααHb [αα-cross-linked HBOC with low oxygen affinity; n=4-6/group]). Sham rats acted as control. Animals were euthanized at 2, 6, and 12 hours after ET; brain tissue was harvested and processed for analysis. RESULTS: In MP4OX animals, the number of neurons that overexpressed the hypoxia-inducible factor (HIF)-1α was higher than in ααHb, particularly at the early time points. In addition, MP4OX was associated with greater phosphorylation of protein kinase B (Akt), a well-known cytoprotective factor. Indeed, the degree of apoptosis, measured as terminal deoxynucleotidyl transferase-positive neurons and caspase-3 cleavage, ranked in order of MP4OX < Hextend < ααHb. CONCLUSION: Even though both HBOCs showed increased levels of HIF-1α compared to shams or Hextend-treated animals, differences in signaling events resulted in very different outcomes for the two HBOCs. ααHb-treated brain tissue showed significant neuronal damage, measured as apoptosis. This was in stark contrast to the protection seen with MP4OX, apparently due to recruitment of Akt and neuronal specific HIF-1α pathways.


Asunto(s)
Apoptosis/efectos de los fármacos , Aspirina/análogos & derivados , Sustitutos Sanguíneos/farmacología , Encéfalo/efectos de los fármacos , Hemoglobinas/farmacología , Hemorragia/terapia , Derivados de Hidroxietil Almidón/farmacología , Hipoxia Encefálica/prevención & control , Maleimidas/farmacología , Neuronas/efectos de los fármacos , Oxígeno/sangre , Polietilenglicoles/farmacología , Animales , Aspirina/farmacología , Aspirina/uso terapéutico , Sustitutos Sanguíneos/uso terapéutico , Encéfalo/patología , Hipoxia de la Célula/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Recambio Total de Sangre , Hemodilución , Hemoglobinas/uso terapéutico , Hemorragia/complicaciones , Derivados de Hidroxietil Almidón/uso terapéutico , Hipoxia Encefálica/etiología , Subunidad alfa del Factor 1 Inducible por Hipoxia/biosíntesis , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Maleimidas/uso terapéutico , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Neuronas/patología , Polietilenglicoles/uso terapéutico , Proteínas Proto-Oncogénicas c-akt/biosíntesis , Proteínas Proto-Oncogénicas c-akt/genética , Ratas , Ratas Sprague-Dawley
6.
PLoS One ; 9(3): e92417, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24642693

RESUMEN

BACKGROUND: Global cerebral ischemia following cardiac arrest is associated with increased cerebral vasoconstriction and decreased cerebral blood flow, contributing to delayed neuronal cell death and neurological detriments in affected patients. We hypothesize that upregulation of contractile ETB and 5-HT1B receptors, previously demonstrated in cerebral arteries after experimental global ischemia, are a key mechanism behind insufficient perfusion of the post-ischemic brain, proposing blockade of this receptor upregulation as a novel target for prevention of cerebral hypoperfusion and delayed neuronal cell death after global cerebral ischemia. The aim was to characterize the time-course of receptor upregulation and associated neuronal damage after global ischemia and investigate whether treatment with the MEK1/2 inhibitor U0126 can prevent cerebrovascular receptor upregulation and thereby improve functional outcome after global cerebral ischemia. Incomplete global cerebral ischemia was induced in Wistar rats and the time-course of enhanced contractile responses and the effect of U0126 in cerebral arteries were studied by wire myography and the neuronal cell death by TUNEL. The expression of ETB and 5-HT1B receptors was determined by immunofluorescence. RESULTS: Enhanced vasoconstriction peaked in fore- and midbrain arteries 3 days after ischemia. Neuronal cell death appeared initially in the hippocampus 3 days after ischemia and gradually increased until 7 days post-ischemia. Treatment with U0126 normalised cerebrovascular ETB and 5-HT1B receptor expression and contractile function, reduced hippocampal cell death and improved survival rate compared to vehicle treated animals. CONCLUSIONS: Excessive cerebrovascular expression of contractile ETB and 5-HT1B receptors is a delayed response to global cerebral ischemia peaking 3 days after the insult, which likely contributes to the development of delayed neuronal damage. The enhanced cerebrovascular contractility can be prevented by treatment with the MEK1/2 inhibitor U0126, diminishes neuronal damage and improves survival rate, suggesting MEK1/2 inhibition as a novel strategy for early treatment of neurological consequences following global cerebral ischemia.


Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Butadienos/farmacología , Hipoxia Encefálica/prevención & control , Nitrilos/farmacología , Receptor de Endotelina B/metabolismo , Receptor de Serotonina 5-HT1B/metabolismo , Animales , Isquemia Encefálica/patología , Butadienos/uso terapéutico , Circulación Cerebrovascular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , MAP Quinasa Quinasa 1/antagonistas & inhibidores , MAP Quinasa Quinasa 1/metabolismo , MAP Quinasa Quinasa 2/antagonistas & inhibidores , MAP Quinasa Quinasa 2/metabolismo , Nitrilos/uso terapéutico , Ratas , Ratas Wistar , Receptor de Endotelina B/genética , Receptor de Serotonina 5-HT1B/genética , Resultado del Tratamiento , Regulación hacia Arriba/efectos de los fármacos , Vasoconstricción/efectos de los fármacos
8.
Neuroscience ; 194: 372-9, 2011 Oct 27.
Artículo en Inglés | MEDLINE | ID: mdl-21640166

RESUMEN

The creatine-phosphocreatine shuttle is essential for the maintenance of cellular ATP, particularly under hypoxic conditions when respiration may become anaerobic. Using a model of intrapartum hypoxia in the precocial spiny mouse (Acomys cahirinus), the present study assessed the potential for maternal creatine supplementation during pregnancy to protect the developing brain from the effects of birth hypoxia. On day 38 of gestation (term is 39 days), the pregnant uterus was isolated and placed in a saline bath for 7.5 min, inducing global hypoxia. The pups were then removed, resuscitated, and cross-fostered to a nursing dam. Control offspring were delivered by caesarean section and recovered immediately after release from the uterus. At 24 h after birth hypoxia, the brains of offspring from dams fed a normal diet showed significant increases in lipid peroxidation as measured by the amount of malondialdehyde. In the cortical subplate, thalamus and piriform cortex there were significant increases in cellular expression of the pro-apoptotic protein BAX, cytoplasmic cytochrome c and caspase-3. When pregnant dams were fed the creatine supplemented diet, the increase in malondialdehyde, BAX, cytochrome c and caspase 3 were almost completely prevented, such that they were not different from control (caesarean-delivered) neonates. This study provides evidence that the neuroprotective capacity of creatine in the hypoxic perinatal brain involves abrogation of lipid peroxidation and apoptosis, possibly through the maintenance of mitochondrial function. Further investigation into these mechanisms of protection, and the long-term development and behavioural outcomes of such neonates is warranted.


Asunto(s)
Creatina/farmacología , Suplementos Dietéticos , Hipoxia Fetal/prevención & control , Hipoxia Encefálica/prevención & control , Complicaciones del Embarazo/dietoterapia , Animales , Animales Recién Nacidos , Creatina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Hipoxia Fetal/complicaciones , Hipoxia Fetal/fisiopatología , Hipoxia Encefálica/etiología , Hipoxia Encefálica/fisiopatología , Masculino , Murinae , Embarazo , Complicaciones del Embarazo/etiología , Complicaciones del Embarazo/fisiopatología
9.
Neurosci Lett ; 471(2): 89-93, 2010 Mar 03.
Artículo en Inglés | MEDLINE | ID: mdl-20079805

RESUMEN

Aspirin is the most widely used drug for the secondary prevention of ischemic stroke in patients suffering from diabetes mellitus. Moreover virgin olive oil (VOO) administration exerts a neuroprotective effect in healthy rat brain slices. The aim of the present study was to determine the possible influence of VOO administration to streptozotocin-diabetic rats (DR) on the neuroprotective effect of aspirin in rat brain. DR were treated during 3 months with saline, aspirin (2mg/kg/day p.o.), VOO (0.5 mL/kg/day p.o.) or its association; a control normoglycemic group was treated with saline. Brain slices were subjected to oxygen-glucose deprivation before a reoxygenation period. All the treatments significantly reduced lactate dehydrogenase LDH efflux after reoxygenation (-54.1% for aspirin, -51.3% for VOO and -72.9% for aspirin plus VOO). Lipid peroxides in brain slices were also reduced after the treatment with aspirin (-17.90%), VOO (-37.3%) and aspirin plus VOO (-49.2%). Production of nitric oxide after reoxygenation was inhibited by all the treatments (-46.5% for ASA, -48.2% for VOO and -75.8% for ASA plus VOO). The activity of the inducible isoform (iNOS) was inhibited by the three types of treatment (-31.8% for ASA, -29.1% for VOO and -56.0% for ASA plus VOO). The main conclusion of our study is that daily oral administration of VOO to diabetic rats may be a natural way to increase the neuroprotective effect of aspirin in diabetic animals.


Asunto(s)
Aspirina/farmacología , Encéfalo/efectos de los fármacos , Diabetes Mellitus Tipo 1/complicaciones , Hipoxia Encefálica/prevención & control , Fármacos Neuroprotectores/farmacología , Aceites de Plantas/farmacología , Animales , Encéfalo/metabolismo , Diabetes Mellitus Experimental/complicaciones , Hipoxia Encefálica/etiología , Hipoxia Encefálica/metabolismo , Técnicas In Vitro , L-Lactato Deshidrogenasa/metabolismo , Peroxidación de Lípido , Masculino , Óxido Nítrico/biosíntesis , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Aceite de Oliva , Ratas , Ratas Wistar
10.
Transfus Clin Biol ; 15(5): 205-11, 2008 Nov.
Artículo en Francés | MEDLINE | ID: mdl-18930420

RESUMEN

In neurosurgery, the question of the optimal transfusion "trigger" remains a controversial matter. Regarding the brain, the current data are still incomplete, justifying the continuation of experimental and clinical studies. The existing expert advices are based on these rather poor data and would probably evolve after the completion of clinical studies in progress. In spine surgery, the situation is simpler and the transfusional stakes are quite similar to those of orthopedics and traumatology. With regard to hemostasis, standardized recommendations exist depending on the laboratory test results or the anticoagulant treatments of the patient.


Asunto(s)
Transfusión Sanguínea , Procedimientos Neuroquirúrgicos , Anemia/etiología , Anemia/prevención & control , Anemia/terapia , Aneurisma Roto/complicaciones , Aneurisma Roto/cirugía , Pérdida de Sangre Quirúrgica , Transfusión de Sangre Autóloga/instrumentación , Neoplasias del Sistema Nervioso Central/irrigación sanguínea , Neoplasias del Sistema Nervioso Central/cirugía , Hemorragia Cerebral/etiología , Hemorragia Cerebral/cirugía , Hemorragia Cerebral/terapia , Circulación Cerebrovascular/fisiología , Traumatismos Craneocerebrales/cirugía , Embolización Terapéutica , Transfusión de Eritrocitos , Hemostasis Quirúrgica/métodos , Humanos , Hipoxia/etiología , Hipoxia/prevención & control , Hipoxia Encefálica/etiología , Hipoxia Encefálica/fisiopatología , Hipoxia Encefálica/prevención & control , Aneurisma Intracraneal/complicaciones , Aneurisma Intracraneal/cirugía , Cuidados Intraoperatorios , Complicaciones Intraoperatorias/prevención & control , Complicaciones Intraoperatorias/terapia , Monitoreo Intraoperatorio
11.
Eur J Pharmacol ; 569(1-2): 94-102, 2007 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-17509557

RESUMEN

Hyperbaric oxygen has been found to be beneficial in treating heatstroke animals. We attempted to further assess the possible mechanism of therapeutic protection offered by hyperbaric oxygen in experimental heatstroke. Anesthetized rats, immediately after the onset of heatstroke, were randomized into the following groups and given: a) hyperbaric oxygen (100% O(2) at 253 kPa for 1 h); or b) normal air. They were exposed to 43 degrees C temperature to induce heatstroke. When the untreated rats underwent heat stress, their survival time values were found to be 20-24 min. Resuscitation with hyperbaric oxygen increased the survival time to new values of 152-176 min. All untreated heatstroke rats displayed cerebrovascular dysfunction (evidenced by hypotension, intracranial hypertension, and cerebral hypoperfusion, hypoxia, and ischemia), hypercoagulable state (evidenced by increased levels of activated partial thromboplastin time, prothrombin time, and D-dimer, but decreased values of platelet count and protein C in plasma), and tissue ischemia/injury (evidenced by increased levels of creatinine, serum urea nitrogen, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase in plasma, and dihydrobenzoic acid, lipid peroxidation, and oxidized-form glutathione/reduced-form of glutathione ratio in hypothalamus). The cerebrovascular dysfunctions, hypercoagulable state, tissue ischemia/injury, and brain oxidative stress that occurred during heatstroke were all suppressed by hyperbaric oxygen therapy. The current results indicate that hyperbaric oxygen therapy may resuscitate rats that had a heatstroke by decreasing multiple organ dysfunction and brain oxidative stress.


Asunto(s)
Golpe de Calor/terapia , Oxigenoterapia Hiperbárica/métodos , Hipoxia Encefálica/prevención & control , Insuficiencia Multiorgánica/prevención & control , Estrés Oxidativo , Animales , Isquemia Encefálica/etiología , Isquemia Encefálica/fisiopatología , Isquemia Encefálica/prevención & control , Modelos Animales de Enfermedad , Glutatión/metabolismo , Disulfuro de Glutatión/metabolismo , Golpe de Calor/etiología , Golpe de Calor/fisiopatología , Calor/efectos adversos , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Hipotálamo/patología , Hipoxia Encefálica/etiología , Hipoxia Encefálica/fisiopatología , Hipertensión Intracraneal/etiología , Hipertensión Intracraneal/fisiopatología , Hipertensión Intracraneal/prevención & control , Pruebas de Función Renal , Peroxidación de Lípido/efectos de los fármacos , Pruebas de Función Hepática , Masculino , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/fisiopatología , Ratas , Ratas Sprague-Dawley , Análisis de Supervivencia , Trombofilia/etiología , Trombofilia/fisiopatología , Trombofilia/prevención & control , Factores de Tiempo , Resultado del Tratamiento
12.
Space Med Med Eng (Beijing) ; 18(4): 303-5, 2005 Aug.
Artículo en Chino | MEDLINE | ID: mdl-16224855

RESUMEN

OBJECTIVE: To observe the protective effects of Rhodiola-astragalus membranaceus mixture against brain damage during hypoxia under simulated plateau environment and the mechanisms maybe involved in. METHOD: Adult SD rats were randomly divided into 3 groups, which were normoxic control, simulated plateau hypoxia, and Rhodiola-astragalus membranaceus mixture pretreatment group. Rats in the latter two groups were exposed to simulated 8000 m altitude in a hypobaric chamber for 7 h. Water content, Na+, K(+)-ATPase activity and SOD activity in cerebral tissue, malondialdehyde (MDA) and lactic acid content in cerebral homogenate and serum were measured. RESULT: As compared with control group, cerebral water content was significantly higher in hypoxia group, while it was obviously lower in pretreatment group. MDA contents of hypoxia group both in cerebral homogenate and serum were higher than that of control group, while the pretreatment group they were both decreased obviously. Lactic acid content of hypoxia group in cerebral and in serum increased markedly and decreased drastically in pretreatment group compared to that of hypoxic group. CONCLUSION: Rhodiola-astragalus membranaceus mixture has preventive effects on hypoxic damage induced by simulated plateau environment. This prevention may be related to the antagonistic effect on membrane lipid peroxidation and the inhibition on the accumulation of lactic acid in brain tissue and serum.


Asunto(s)
Altitud , Astragalus propinquus , Medicamentos Herbarios Chinos/farmacología , Hipoxia Encefálica/prevención & control , Rhodiola , Adenosina Trifosfatasas/efectos de los fármacos , Adenosina Trifosfatasas/metabolismo , Animales , Cámaras de Exposición Atmosférica , Proteínas de Transporte de Catión , Líquido Extracelular/efectos de los fármacos , Hipoxia Encefálica/tratamiento farmacológico , Ácido Láctico/metabolismo , Malondialdehído/metabolismo , Fitoterapia , Ratas , Ratas Sprague-Dawley , Sodio/metabolismo , Superóxido Dismutasa/efectos de los fármacos , Superóxido Dismutasa/metabolismo
13.
Brain Res ; 1019(1-2): 47-54, 2004 Sep 03.
Artículo en Inglés | MEDLINE | ID: mdl-15306237

RESUMEN

Epigallocatechin gallate (EGCG), a major constituent of green tea, is a potent free radical scavenger. The purpose of this study was to verify whether EGCG reduces focal ischemia/reperfusion-induced brain injury in a rat model. Male Sprague-Dawley rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and subjected to a middle cerebral artery 2 h occlusion and then a 24-h reperfusion. The EGCG (25 mg and 50 mg/kg, i.p.) or vehicle was administered immediately after reperfusion. Twenty-four hours after reperfusion, infarction size, levels of oxidative stress markers (malondialdehyde and oxidized/total glutathione ratio) in the brain and neurological deficits were evaluated. The dose of 50 mg/kg of EGCG significantly reduced the infarction volume (9.9+/-3.2%) as compared to those (45.6+/-5.3%, 34.5+/-7.8%) of the control group and the EGCG 25 mg/kg treated group (p<0.01). The dose of 50 mg/kg of EGCG significantly reduced the neurological deficit total score (5.2+/-1.7) as compared to those (9.5+/-1.2, 8.5+/-2.5) of the control group and the EGCG 25 mg/kg treated group (p<0.05). The dose of 50 mg/kg of EGCG significantly attenuated the level of malondialdehyde and the level of oxidized/total glutathione ratio (281+/-66 nmol/g and 0.48+/-0.03) as compared to the those (415+/-46 nmol/g and 0.64+/-0.05, 381+/-51 nmol/g and 0.61+/-0.06) of the control group and the EGCG 25 mg/kg treated group (p<0.05). These results demonstrate the anti-oxidant effects of EGCG (50 mg/kg) in a rat model of transient focal ischemia, which is a likely explanation for EGCG's neuroprotective effects.


Asunto(s)
Catequina/análogos & derivados , Catequina/uso terapéutico , Hipoxia Encefálica/prevención & control , Infarto de la Arteria Cerebral Media/prevención & control , Fármacos Neuroprotectores/uso terapéutico , Animales , Catequina/farmacología , Hipoxia Encefálica/tratamiento farmacológico , Hipoxia Encefálica/patología , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Infarto de la Arteria Cerebral Media/patología , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Masculino , Fármacos Neuroprotectores/farmacología , Ratas , Ratas Sprague-Dawley
14.
Biol Pharm Bull ; 27(7): 1081-5, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15256744

RESUMEN

We studied the cognitive improving and cerebral protective constituents in the roots of Polygala tenuifolia Willdenow, a well-known Chinese traditional medicine prescribed for amnesia, neurasthenia, palpitation, noctural emission and insomnia. Tenuifoliside B (1), which is one of the acylated oligosaccharides in the roots of P. tenuifolia, showed the cerebral protective effect on potassium cyanide (KCN)-induced anoxia in mice, widely used as an animal model for cerebrovascular disease, and also had an ameliorative effect on the scopolamine-induced impairment of performance in passive avoidance task in rats. Compound 1 significantly enhanced oxotremorine-induced tremors in mice, suggesting that it ameliorated the scopolamine-induced impairment of passive avoidance response by enhancing the cholinergic system. These findings show that compound 1 has cognitive improving and cerebral protective effects.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Hipoxia Encefálica/prevención & control , Fármacos Neuroprotectores/uso terapéutico , Nootrópicos/uso terapéutico , Oligosacáridos/uso terapéutico , Polygala , Acilación/efectos de los fármacos , Animales , Reacción de Prevención/efectos de los fármacos , Reacción de Prevención/fisiología , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/aislamiento & purificación , Medicamentos Herbarios Chinos/farmacología , Hipoxia Encefálica/fisiopatología , Masculino , Ratones , Ratones Endogámicos ICR , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/farmacología , Nootrópicos/aislamiento & purificación , Nootrópicos/farmacología , Oligosacáridos/aislamiento & purificación , Oligosacáridos/farmacología , Raíces de Plantas , Ratas , Ratas Wistar
16.
Clin Exp Pharmacol Physiol ; 30(1-2): 44-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12542452

RESUMEN

1. We showed that a nutritional factor was able to attenuate the development of hypertension and its related diseases in stroke-prone spontaneously hypertensive rats (SHRSP). In the present study, the effect of Wakame, an edible brown seaweed, on the development of stroke was examined in SHRSP. 2. We studied the treatment with 5% (w/w in a diet) Wakame powder in salt-loaded (0.5% NaCl in drinking water) SHRSP. Salt-loaded animals treated with 5% cellulose or kaolin were used as controls. Wakame significantly delayed the development of stroke signs (P < 0.05) and significantly improved the survival rate of salt-loaded SHRSP (P < 0.05). There was no significant difference in the elevation of blood pressure among the three groups during the observation period. 3. We isolated fucoxanthin, a carotinoid, from Wakame powder and studied its preventive effect on ischaemic cultured neuronal cell death. Fucoxanthin significantly attenuated neuronal cell injury in hypoxia and re-oxygenation (P < 0.05). 4. Based on these results, we conclude that Wakame has a beneficial effect on cerebrovascular diseases in SHRSP, independent of hypertension. It is possible that fucoxanthin in Wakame may have a preventive effect against ischaemic neuronal cell death seen in SHRSP with stroke.


Asunto(s)
Eucariontes/química , Extractos Vegetales/farmacología , Accidente Cerebrovascular/prevención & control , Animales , Presión Sanguínea/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Isquemia Encefálica/complicaciones , Isquemia Encefálica/patología , Isquemia Encefálica/prevención & control , Muerte Celular/efectos de los fármacos , Células Cultivadas , Hipertensión/inducido químicamente , Hipertensión/complicaciones , Hipertensión/fisiopatología , Hipertensión/prevención & control , Hipoxia Encefálica/complicaciones , Hipoxia Encefálica/patología , Hipoxia Encefálica/prevención & control , Neuronas/efectos de los fármacos , Neuronas/patología , Extractos Vegetales/química , Ratas , Ratas Endogámicas SHR , Cloruro de Sodio/farmacología , Accidente Cerebrovascular/inducido químicamente , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/fisiopatología , Xantófilas/análisis , Xantófilas/farmacología
18.
Stroke ; 26(10): 1883-7, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7570743

RESUMEN

BACKGROUND AND PURPOSE: L-Deprenyl (Selegiline) protects animal brains against toxic substances such as 1-methyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine. Experiments were conducted to test whether L-deprenyl prevents or reduces cerebral damage in a transient hypoxia/ischemia rat model. METHODS: Rats were treated for 14 days with 2 mg/kg and 10 mg/kg L-deprenyl or saline. After surgery a 20-minute hypoxia/ischemia period was induced by simultaneous occlusion of the left common carotid artery and reduction of the percentage of oxygen in the gas mixture to 10%. Rats were killed 24 hours later. Silver staining was used to reveal damage in several brain regions. RESULTS: In the brain, both L-deprenyl dosages reduced damage up to 78% compared with the controls. Total brain damage was decreased from 23%-31% to 5%-9% with the L-deprenyl treatment (2 mg/kg: F1.13 = 6.956, P < .05; 10 mg/kg: F1.13 = 5.731, P < .05). In the striatum, significant treatment effects were found between both the L-deprenyl groups (2 mg/kg and 10 mg/kg, respectively) and the saline group (F1.13 = 14.870, P < .005; and F1.13 = 8.937, P = .01; respectively). In the thalamus, significant treatment effects were seen in the 2-mg/kg L-deprenyl group (F1.13 = 11.638, P < .005) and the 10-mg/kg group (F1.13 = 8.347, P < .05) compared with the control group. No significant damage decrease was seen in the hippocampus and the cortex. CONCLUSIONS: The results show that L-deprenyl is effective as a prophylactic treatment for brain tissue when it is administered before hypoxia/ischemia. Mechanisms responsible for the observed protection remain unclear. The regional differences in damage, however, are in accordance with the reported regional increase in superoxide dismutase and catalase activities after L-deprenyl treatment, suggesting the involvement of free radicals and scavenger enzymes.


Asunto(s)
Hipoxia Encefálica/prevención & control , Ataque Isquémico Transitorio/prevención & control , Inhibidores de la Monoaminooxidasa/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Selegilina/uso terapéutico , Animales , Encéfalo/efectos de los fármacos , Encéfalo/patología , Catalasa/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/patología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/patología , Hipocampo/efectos de los fármacos , Hipocampo/patología , Hipoxia Encefálica/patología , Ataque Isquémico Transitorio/patología , Masculino , Inhibidores de la Monoaminooxidasa/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Prosencéfalo/efectos de los fármacos , Prosencéfalo/patología , Ratas , Ratas Wistar , Selegilina/administración & dosificación , Superóxido Dismutasa/metabolismo , Tálamo/efectos de los fármacos , Tálamo/patología
19.
J Ethnopharmacol ; 40(3): 201-6, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8145576

RESUMEN

The protective effect of Hachimi-jio-gan (HJ) against cerebral anoxia was investigated with various experimental models in mice. Minimal effective dose of HJ which significantly prolonged the survival time was 0.5 g/kg, p.o. for normobaric hypoxia and 0.5 g/kg, p.o. for KCN- (4 mg/kg, i.v.) induced anoxia. HJ reduced the duration of coma induced by a sublethal dose of KCN (1.8 mg/kg, i.v.) in a dose-dependent manner. Furthermore HJ potentiated the anti-anoxic effect of physostigmine and the effect of HJ was diminished by the treatment with atropine.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Hipoxia Encefálica/prevención & control , Animales , Atropina/farmacología , Sinergismo Farmacológico , Hipoxia Encefálica/inducido químicamente , Masculino , Ratones , Ratones Endogámicos , Fisostigmina/farmacología , Cianuro de Potasio
20.
Anesteziol Reanimatol ; (6): 51-6, 1993.
Artículo en Ruso | MEDLINE | ID: mdl-8185076

RESUMEN

Biogenic amine metabolism in severe brain trauma has been analysed in 165 patients whose brain was protected from hypoxia with GOBA and thiobarbiturates in subnarcotic doses (116 cases) and the combination of the above agents with an early course of HBO (49 cases). The peculiarities of biogenic amine metabolism have been established in patients recovered and those who died later. As any activation of biogenic amine systems realizing stress enhances disadaptation processes, it is recommended to begin a course of HBO upon their stabilization.


Asunto(s)
Aminas Biogénicas/metabolismo , Lesiones Encefálicas/metabolismo , Hipoxia Encefálica/prevención & control , Adolescente , Adulto , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/terapia , Terapia Combinada , Humanos , Oxigenoterapia Hiperbárica , Hipoxia Encefálica/etiología , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA